Conclusion
The simulated incidence of stroke/SE incidence and major bleeding might
reflect the real-world event rate in AF patients. Even some differences
existed in the absolute rates of stroke/SE and major bleeding between
observed and simulated studies, the results confirmed similar
effectiveness and safety to ROCKET AF comparing rivaroxaban and warfarin
in AF patients.
Keywords :rivaroxaban; atrial fibrillation (AF); simulation; randomized controlled
trial (RCT); observational study